Treatment Recommendations for Patients with Inadequate Glycemic Control

Current Treatment Assessment

• The American Diabetes Association recommends treatment intensification when A1C is ≥1.5% above the individualized glycemic goal (typically 7.0%) 1
• Patients with HbA1c of 9.0% on metformin 1000mg bid and empagliflozin 25mg daily indicate inadequate glycemic control despite being on dual therapy with metformin and an SGLT2 inhibitor (empagliflozin) 1

Recommended Treatment Intensification

• The American Diabetes Association recommends adding a GLP-1 receptor agonist to the current regimen of metformin and empagliflozin for patients with inadequate glycemic control 1, 2
• GLP-1 RAs provide significant A1C reduction (1-2% lowering when added to metformin) and offer additional benefits beyond glycemic control, including weight reduction 2, cardiovascular risk reduction in patients with established ASCVD 3, and low risk of hypoglycemia 2

Rationale for GLP-1 RA Addition

• The combination of metformin, SGLT2 inhibitor, and GLP-1 RA addresses multiple pathophysiological defects in type 2 diabetes, providing superior glycemic control compared to adding a third oral agent 4
• Metformin decreases hepatic glucose production and improves insulin sensitivity, while GLP-1 RA enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying 1, 4

Implementation Considerations

• Regular reassessment every 3-6 months is recommended to avoid therapeutic inertia and ensure timely treatment intensification 2, 3
• Monitoring of HbA1c after 3 months of therapy adjustment, vitamin B12 levels in patients on long-term metformin therapy, and renal function are crucial for optimal patient care 1, 3

Common Pitfalls to Avoid

• Therapeutic inertia, ignoring cardiovascular and renal benefits, overlooking combination products, and inadequate follow-up can hinder optimal patient outcomes 2, 4, 3

Management of Type 2 Diabetes with Elevated A1C

Treatment Intensification Strategy

• The American Diabetes Association recommends reserving insulin for patients with severe hyperglycemia, ketosis/ketoacidosis, or those who fail triple therapy, with GLP-1 receptor agonists achieving equivalent or superior A1C reduction without the weight gain and hypoglycemia risk associated with insulin 5, 6

Implementation Plan

• Before initiating a GLP-1 receptor agonist, it is essential to screen for cardiovascular disease, heart failure, and chronic kidney disease, and exclude contraindications to GLP-1 receptor agonists, such as a history of medullary thyroid carcinoma or MEN-2 5, 6